Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth
- 29 October 2014
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 3 (3) , 408-416
Abstract
Hybrid liposomal nanoparticles for systemic delivery of axitinib inhibit hypoxic tumor growth.Keywords
This publication has 42 references indexed in Scilit:
- Single-Step Assembly of DOX/ICG Loaded Lipid–Polymer Nanoparticles for Highly Effective Chemo-photothermal Combination TherapyACS Nano, 2013
- Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapyTrends in Pharmacological Sciences, 2012
- Anti-HIF-1α antibody-conjugated pluronic triblock copolymers encapsulated with Paclitaxel for tumor targeting therapyBiomaterials, 2010
- Protein release kinetics for core–shell hybrid nanoparticles based on the layer-by-layer assembly of alginate and chitosan on liposomesBiomaterials, 2008
- Therapeutic targeting of the tumor microenvironmentCancer Cell, 2005
- Hypoxia-inducible factor (HIF-1)α: its protein stability and biological functionsExperimental & Molecular Medicine, 2004
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- Dissemination and growth of cancer cells in metastatic sitesNature Reviews Cancer, 2002
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI: Journal of the National Cancer Institute, 1990
- Phospholipid-cholesterol interaction. Kinetics of water permeability in liposomesBiochemistry, 1972